STOCK TITAN

180 Life Sciences Corp. - $ATNF STOCK NEWS

Welcome to our dedicated page for 180 Life Sciences news (Ticker: $ATNF), a resource for investors and traders seeking the latest updates and insights on 180 Life Sciences stock.

180 Life Sciences Corp. Common Stock (symbol: ATNF) represents a pioneering clinical-stage biotechnology company based in Menlo Park, California. The company focuses on developing innovative therapeutics to address unmet medical needs in chronic pain, inflammation, and fibrosis.

The company has several key product development platforms currently in Phase IIb/III clinical trials:

  • Fibrosis and Anti-TNF Platform: This platform targets the treatment of fibrosis and anti-tumor necrosis factors, a major cause of inflammation.
  • Synthetic Cannabidiol (CBD) Analogs Platform: This platform includes man-made derivatives of CBD designed to offer therapeutic benefits.
  • α7nAChR Platform: Focused on the alpha 7 nicotinic acetylcholine receptor, which plays a role in modulating inflammation and pain.

180 Life Sciences Corp. is committed to advancing its drug candidates through robust clinical trials and cutting-edge research. From addressing postoperative pain relief with orally absorbed CBD tablets to combating chronic inflammation and fibrosis, the company's innovative approach highlights its significance in the biotechnology landscape.

The company’s recent achievements include a notable presentation by Dr. Michael J. Alaia at the 2022 American Academy of Orthopaedic Surgeons Annual Meeting. The talk focused on the efficacy of CBD tablets for postoperative pain relief, showcasing the potential impact of 180 Life Sciences Corp.'s therapies.

For more information, investors can contact Jason Assad, Director of Investor Relations, at jassad@180lifesciences.com.

-
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.49%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.86%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.36%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.66%
Tags
none
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.02%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.51%
Tags
none

FAQ

What does 180 Life Sciences Corp. specialize in?

180 Life Sciences Corp. specializes in developing therapeutics for chronic pain, inflammation, and fibrosis.

Where is 180 Life Sciences Corp. headquartered?

The company is headquartered in Menlo Park, California.

What are the key platforms of 180 Life Sciences Corp.?

The key platforms are the Fibrosis and Anti-TNF Platform, Synthetic Cannabidiol (CBD) Analogs Platform, and the α7nAChR Platform.

What stage are the company's product development platforms in?

The platforms are currently in Phase IIb/III clinical trials.

Who can be contacted for investor relations?

Investors can contact Jason Assad, Director of Investor Relations, at jassad@180lifesciences.com.

What is the focus of the recent talk presented by Dr. Michael J. Alaia?

Dr. Alaia's talk focused on the efficacy of an orally absorbed CBD tablet for postoperative pain relief following rotator cuff surgery.

What is the company's ticker symbol?

The ticker symbol for 180 Life Sciences Corp. is ATNF.

What unmet medical needs does 180 Life Sciences Corp. aim to address?

The company aims to address unmet needs in chronic pain, inflammation, and fibrosis.

What is the significance of the α7nAChR platform?

The α7nAChR platform focuses on the alpha 7 nicotinic acetylcholine receptor, which is important in modulating inflammation and pain.

How can I stay updated with the latest news about 180 Life Sciences Corp.?

You can stay updated by checking the latest news on the company's official website or contacting their investor relations.

180 Life Sciences Corp.

Nasdaq:ATNF

ATNF Rankings

ATNF Stock Data

1.46M
765.12k
3.35%
11.2%
4.97%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
PALO ALTO